article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. 3 Nature Aging | VOL 1 | July 2021 | p.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials. The Court’s order permits petitioners to return to the Court of Appeals “in the event” that DEA engages in “significant delays” in the future.

DEA 104
article thumbnail

Cannabis laws in Japan: Is weed legal?

The Cannigma

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition.

Law 137
article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Psilocybin’s therapeutic benefits are so promising that Denver, Colorado became the first city to decriminalize psilocybin in May 2019, and in 2020, Oregon passed Measure 109, which paved the road for a program allowing for legal manufacture, delivery, and administration of psilocybin to clients at supervised, licensed facilities in the state.

DEA 52
article thumbnail

Cannabis Use In Active Athletes: Behaviors Related to Subjective Effects

Puff Puff Post

July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. BOULDER, Colo.

article thumbnail

Cannabis Use In Active Athletes: Behaviors Related to Subjective Effects

Puff Puff Post

July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. BOULDER, Colo.